EA201400590A1 - Устойчивая к разрушению пероральная фармацевтическая лекарственная форма, содержащая фармакологически активный ингредиент, опиоидный антагонист и/или средство, вызывающее отвращение, полиалкиленоксид и анионный полимер - Google Patents

Устойчивая к разрушению пероральная фармацевтическая лекарственная форма, содержащая фармакологически активный ингредиент, опиоидный антагонист и/или средство, вызывающее отвращение, полиалкиленоксид и анионный полимер

Info

Publication number
EA201400590A1
EA201400590A1 EA201400590A EA201400590A EA201400590A1 EA 201400590 A1 EA201400590 A1 EA 201400590A1 EA 201400590 A EA201400590 A EA 201400590A EA 201400590 A EA201400590 A EA 201400590A EA 201400590 A1 EA201400590 A1 EA 201400590A1
Authority
EA
Eurasian Patent Office
Prior art keywords
active ingredient
dosage form
pharmaceutical dosage
pharmacologically active
polyalkylene oxide
Prior art date
Application number
EA201400590A
Other languages
English (en)
Inventor
Аня Гайсслер
Лутц Барншайд
Зебастиан Швир
Иоганнес Бартоломойс
Original Assignee
Грюненталь Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47191746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201400590(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Грюненталь Гмбх filed Critical Грюненталь Гмбх
Publication of EA201400590A1 publication Critical patent/EA201400590A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Abstract

Изобретение относится к фармацевтической лекарственной форме для перорального введения, которая имеет прочность на разрыв по меньшей мере 300 Н и которая содержит (I) фармакологически активный ингредиент; (II) опиоидный антагонист и/или средство, вызывающее отвращение; (III) полиалкиленоксид, который имеет среднюю молекулярную массу по меньшей мере 200000 г/моль; и (а) которая содержит (IV) анионный полимер и/или (б) имеет стабильность при хранении при 40°С по меньшей мере 3 месяца.
EA201400590A 2011-11-17 2012-11-15 Устойчивая к разрушению пероральная фармацевтическая лекарственная форма, содержащая фармакологически активный ингредиент, опиоидный антагонист и/или средство, вызывающее отвращение, полиалкиленоксид и анионный полимер EA201400590A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11009129 2011-11-17
EP12001295 2012-02-28
PCT/EP2012/072678 WO2013072395A1 (en) 2011-11-17 2012-11-15 Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer

Publications (1)

Publication Number Publication Date
EA201400590A1 true EA201400590A1 (ru) 2014-11-28

Family

ID=47191746

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400590A EA201400590A1 (ru) 2011-11-17 2012-11-15 Устойчивая к разрушению пероральная фармацевтическая лекарственная форма, содержащая фармакологически активный ингредиент, опиоидный антагонист и/или средство, вызывающее отвращение, полиалкиленоксид и анионный полимер

Country Status (17)

Country Link
US (1) US20130129826A1 (ru)
EP (1) EP2780000B1 (ru)
JP (1) JP6085307B2 (ru)
KR (1) KR20140096062A (ru)
CN (1) CN104066426A (ru)
AR (1) AR088875A1 (ru)
AU (1) AU2012338872B2 (ru)
BR (1) BR112014011504A2 (ru)
CA (1) CA2855718A1 (ru)
CL (1) CL2014000904A1 (ru)
CO (1) CO7210299A2 (ru)
EA (1) EA201400590A1 (ru)
HK (1) HK1200742A1 (ru)
IL (1) IL232054A0 (ru)
MX (1) MX349725B (ru)
PE (1) PE20141671A1 (ru)
WO (1) WO2013072395A1 (ru)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
WO2009135680A1 (en) 2008-05-09 2009-11-12 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
CN102639118B (zh) * 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
HUE034710T2 (hu) 2011-07-29 2018-02-28 Gruenenthal Gmbh Visszaéléssel szemben ellenálló, azonnali hatóanyagfelszabadulást biztosító tabletta
DK2736495T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Misbrugsbestandig tablet som tilvejebringer øjeblikkelig frigivelse af lægemiddel
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
WO2013156453A1 (en) 2012-04-18 2013-10-24 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2877161A1 (en) 2012-07-06 2015-06-03 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
BR112015000320B1 (pt) * 2012-07-12 2023-03-07 SpecGx LLC Composições farmacêuticas dissuasivas de abuso e seu processo de preparação
AU2014273226B2 (en) 2013-05-29 2019-06-27 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
CN103304570A (zh) * 2013-07-12 2013-09-18 四川省惠达药业有限公司 一种盐酸纳洛酮化合物、其制备方法及其药物组合物
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2929866A1 (en) * 2013-12-23 2015-07-02 Purdue Pharma L.P. Opioid antagonist formulations
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3174534A1 (en) * 2014-08-01 2017-06-07 KRKA, d.d., Novo mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
AU2016251302A1 (en) 2015-04-24 2017-11-23 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix
CA2983640A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from different particles
US20160310437A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
CA2983642A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018520165A (ja) * 2015-07-10 2018-07-26 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ ヒドロコドンの多数錠剤乱用抵抗性即時放出型固体投薬形態物
DE202016005375U1 (de) * 2015-09-03 2016-09-30 Acino Pharma Ag Verminderung der Deallylierung von Naloxon während der Lagerung einer naloxonhaltigen Retardformulierung
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
JP7244536B2 (ja) 2018-04-06 2023-03-22 キャプシュゲル・ベルジウム・エヌ・ヴィ メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法
CN115337440B (zh) * 2022-08-22 2024-03-29 南通大学 一种促进伤口复原的纳米敷料及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT914097E (pt) * 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
DE60238756D1 (de) * 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
AU2002321879A1 (en) 2001-08-06 2003-03-03 Thomas Gruber Pharmaceutical formulation containing dye
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
EP2316428A1 (en) 2002-04-05 2011-05-04 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
PL1842533T3 (pl) * 2003-08-06 2013-08-30 Gruenenthal Gmbh Postać aplikacyjna zabezpieczona przed nadużyciem
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
EP1740156B8 (de) 2004-04-22 2012-07-11 Grünenthal GmbH Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform
AU2005259476B2 (en) 2004-07-01 2010-07-29 Gruenenthal Gmbh Oral dosage form safeguarded against abuse
KR101204657B1 (ko) 2004-07-01 2012-11-27 그뤼넨탈 게엠베하 (1r,2r)-3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀을 함유하는 남용 방지 경구 투여 제형
WO2006002883A1 (de) 2004-07-01 2006-01-12 Grünenthal GmbH Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CN102316857A (zh) * 2008-12-16 2012-01-11 莱博法姆公司 防止误用的控释配方
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
WO2012028318A1 (en) * 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
AU2012219322A1 (en) * 2011-02-17 2013-05-09 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
WO2013050539A2 (en) * 2011-10-06 2013-04-11 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist

Also Published As

Publication number Publication date
PE20141671A1 (es) 2014-11-22
JP2014533668A (ja) 2014-12-15
HK1200742A1 (en) 2015-08-14
EP2780000A1 (en) 2014-09-24
US20130129826A1 (en) 2013-05-23
CN104066426A (zh) 2014-09-24
AR088875A1 (es) 2014-07-16
KR20140096062A (ko) 2014-08-04
AU2012338872B2 (en) 2017-06-22
JP6085307B2 (ja) 2017-02-22
NZ623291A (en) 2016-01-29
CL2014000904A1 (es) 2014-08-18
CA2855718A1 (en) 2013-05-23
IL232054A0 (en) 2014-05-28
WO2013072395A1 (en) 2013-05-23
EP2780000B1 (en) 2019-04-03
BR112014011504A2 (pt) 2017-05-09
MX349725B (es) 2017-08-10
AU2012338872A1 (en) 2014-04-17
MX2014005820A (es) 2014-06-04
CO7210299A2 (es) 2015-03-09

Similar Documents

Publication Publication Date Title
EA201400590A1 (ru) Устойчивая к разрушению пероральная фармацевтическая лекарственная форма, содержащая фармакологически активный ингредиент, опиоидный антагонист и/или средство, вызывающее отвращение, полиалкиленоксид и анионный полимер
EA201400413A1 (ru) Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая опиоидный агонист и опиоидный антагонист
EA201401240A1 (ru) Термоформованная, устойчивая к разрушению фармацевтическая лекарственная форма, содержащая цинк
EA201390783A1 (ru) Биоразлагаемые композиции для доставки лекарственных средств
CL2011002969A1 (es) Forma de dosificacion termoformada que presenta una resistencia a la rotura de 300 n que comprende un opioide, 0,001 y 5,0 % de una acido y un oxido de polialquelino con peso molecular de al menos 500.000 g/mol; empaquetamiento que la comprende junto a un secuestrador de oxigeno.
ECSP13012472A (es) Forma de dosificación resistente a alteración que comprende un polímero aniónico
ECSP13012474A (es) Forma de dosificación resistente a manipulación que comprende una sal inorgánica
NZ607479A (en) Tamper resistant dosage form comprising an anionic polymer
EA201492172A1 (ru) Биоразлагаемая композиция для доставки гидрофобных лекарственных средств
EA201390600A1 (ru) Терапевтические наночастицы с сополимерами с большим молекулярным весом
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
PH12014502366A1 (en) Injectable formulation
EA201171271A1 (ru) Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида
SI3079688T1 (en) Chromium derivative as dopamine D3 RECEPTOR-ANTAGONIST FOR USE IN THE TREATMENT OF DISEASE OF AVTISTIC SPECTRUM
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
EP2682129A3 (en) Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous
EA201201530A1 (ru) Комбинация 4-{3-[цис-гексагидроциклопента[c]пиррол-2-(1h)-ил]пропокси} бензамида и антагониста nmda-рецептора и фармацевтические композиции, которые её содержат
EA201201158A1 (ru) Лекарственный препарат, содержащий бензилдиметил[3-(миристоиламино)пропил]аммония хлорид
EA201201329A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
ECSP14000928A (es) Forma de dósis farmacéutica oral a prueba de manipulación que comprende un agente antagonista y/o repelente opioide, óxido de polialquileno y un polímero aniónico
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
TH127248A (th) ปริมาณขนาดยาที่ให้ทางปากของเบนดามัสทีน (oral dosage forms of bendamustine)